167 related articles for article (PubMed ID: 38090373)
1. Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022.
Huang Y; Zhang L
Cancer Innov; 2023 Feb; 2(1):25-35. PubMed ID: 38090373
[TBL] [Abstract][Full Text] [Related]
2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
3. Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer.
Yu L; Wang R; Zhao Y; Wu Y; Wang L; Chen H; He Z; Wang Q; Wu Y
Technol Cancer Res Treat; 2023; 22():15330338231168466. PubMed ID: 37078129
[TBL] [Abstract][Full Text] [Related]
4. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
5. Treatment of ALK-positive nonsmall cell lung cancer: recent advances.
Thai AA; Solomon BJ
Curr Opin Oncol; 2018 Mar; 30(2):84-91. PubMed ID: 29256901
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for lung cancer: Beyond EGFR and ALK.
Herrera-Juárez M; Serrano-Gómez C; Bote-de-Cabo H; Paz-Ares L
Cancer; 2023 Jun; 129(12):1803-1820. PubMed ID: 37073562
[TBL] [Abstract][Full Text] [Related]
8. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review.
Chen J; Xu C; Lv J; Lu W; Zhang Y; Wang D; Song Y
Transl Lung Cancer Res; 2023 Apr; 12(4):895-908. PubMed ID: 37197619
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
11. Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.
Shokoohi A; Al-Hashami Z; Moore S; Pender A; Wong SK; Wang Y; Leung B; Wu J; Ho C
Cancer Med; 2022 Jan; 11(1):86-93. PubMed ID: 34786889
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
13. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y
Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459
[TBL] [Abstract][Full Text] [Related]
15. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X; Martín M; Remon J; Higuera O; Calvo V; Jarabo JR; Conde E; Luna J; Provencio M; De Castro J; López-Ríos F; Hernando-Trancho F; Couñago F
Future Oncol; 2021 Oct; 17(30):4011-4025. PubMed ID: 34337973
[TBL] [Abstract][Full Text] [Related]
17. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
18. How and when to use genetic markers for nonsmall cell lung cancer.
Lazarus DR; Ost DE
Curr Opin Pulm Med; 2013 Jul; 19(4):331-9. PubMed ID: 23715289
[TBL] [Abstract][Full Text] [Related]
19. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.
Chang WC; Kim HK; Shin BK
Oncol Rep; 2020 Jan; 43(1):218-228. PubMed ID: 31746406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]